Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions

EPMA Journal

Volumn 5, Issue 1, 2014, Pages

  Lazarenko, Liudmyla M ^a   Nikitina, Olena E ^b   Nikitin, Evgen V ^b   Demchenko, Olga M ^c,d   Kovtonyuk, Galyna V ^d   Ganova, Larysa O ^a   Bubnov, Rostyslav V ^a,e   Shevchuk, Veronika O ^a   Nastradina, Natalia M ^b   Bila, Viktoria V ^c   Spivak, Mykola Ya ^a,d  

^a ZABOLOTNY INSTITUTE OF MICROBIOLOGY AND VIROLOGY   (Ukraine)

^b ODESSA NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^c JSC SPC 'DiaprofMed'   (Ukraine)

^d Perinatal Center   (Ukraine)

^e Clinical Hospital 'Pheophania' of State Affairs Department   (Ukraine)

Author keywords

Antibodies; Avidity; Biomarker panel; Cervical precancerous lesions; Herpes simplex virus infections; HPV induced cervical precancerous diseases; Immunomodulators; Papillomavirus; Personalized medicine; Predictive; Preventive; Pro and anti inflammatory cytokines; Ultrasonography

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA1; VIRUS DNA;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CANCER RISK; CELL STRUCTURE; COLPOSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT INDICATION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA;

EID: 84902688386     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1186/1878-5085-5-1     Document Type: Article

References (100)

1. Golubnitschaja O, Costigliola V, . EPMA General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European association for predictive preventive and personalised medicine. EPMA J 2012, 3:14. 10.1186/1878-5085-3-14, 3485619, 23116135, EPMA.
2. Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun M, Debald M, Kuhn W, Schild HH. Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?. EPMA J 2013, 4(1):6. doi:10.1186/1878-5085-4-6, 10.1186/1878-5085-4-6, 3615949, 23418957.
3. Debald M, Yeghiazaryan K, Cebioglu M, Kuhn W, Schild HH, Golubnitschaja O. 'Suspect molecular signature' in blood as the indicator of undiagnosed breast cancer, cancer risk and targeted prevention. EPMA J 2013, 4:22. 10.1186/1878-5085-4-22, 3847171, 24228816.
4. Goncharenko VM, Beniuk VA, Demchenko OM, Spivak MY, Bubnov RV. Predictive diagnosis of endometrial hyperplasia and personalized therapeutic strategy in fertile age women. EPMA J 2013, 4:24. 10.1186/1878-5085-4-24, 3866390, 24314145.
5. Comprehensive cervical cancer prevention and control - a healthier future for girls and women WHO guidance note http://www.who.int/reproductivehealth/publications/cancers/9789241505147/en/, Comprehensive cervical cancer prevention and control - a healthier future for girls and women.
6. Hausen H. Human genital cancers: synergism between two virus infections or synergism between a virus infection and initiating events?. Lancet 1982, 320(8312):1370-1372. doi:10.1016/S0140-6736(82)91273-9.
7. Hausen H. Papillomaviruses causing cancer evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000, 92(9):690-698. 10.1093/jnci/92.9.690, 10793105.
8. Kisilev VI. Human papillomaviruses in the development of cervical cancer 2004, Dymytreyd Schedule Group: Moscow.
9. Lazarenko LM, Spivak MY, Mykchailenko OM, Suhih GT, Lakatosh VP. Papillomavirus infection and interferons systems 2008, Fitosociocentr: Kyiv.
10. Szarewski A, Maddox P, Royston P, Jarvis M, Anderson M, Guillebaud J, Cuzick J. The effect of stopping smoking on cervical Langerhans' cell and lymphocytes. BJOG 2002, 108(3):295-303.
11. De Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, Kenter G, Offringa R, van der Burg SH. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004, 64(15):5449-5455. 10.1158/0008-5472.CAN-04-0831, 15289354.
12. Stern PL. Immunity to human papillomavirus-associated cervical neoplasia. Adv Canc Res 1996, 69:175-211.
13. Stanley MA. Immune responses to human papilloma viruses. Indian J Med Res 2009, 130(3):266-276.
14. Hernández-Montes J, Rocha-Zavaleta L, Monroy-García A, Weiss-Steider B, Zaragoza-Ortega Mdel C, Cruz-Talonia FY, Cruz OC, Bonifaz-Alfonso L, Chávez-Rueda AK, Rojo-Aguilar MP, Legorreta-Haquet MV, Mora-García Mde L. Peripheral blood lymphocytes from low-grade squamous intraepithelial lesions patients recognize vaccine antigens in the presence of activated dendritic cells, and produced high levels of CD8 + IFNγ + T cells and low levels of IL-2 when induced to proliferate. Infect Agent Cancer 2012, 7(1):12. doi:10.1186/1750-9378-7-12, 10.1186/1750-9378-7-12, 3406962, 22642942.
15. Lazarenko LN, Lyhyrda NF, Vorobyova LI, Potebnya GP, Demchenko ON, Spivak N. Changing the cytokine profile and indicators of cell immunity in patients with dysplasia, induced by papillomavirus. Obstet Gynecol 2011, 8:72-76.
16. Bleotu C, Chifiriuc MC, Grigore R, Grancea C, Popescu CR, Anton G, Cernescu C. Investigation of Th1/Th2 cytokine profiles in patients with laryngo-pharyngeal HPV-positive cancers. Eur Arch Otorhinolaryngol 2013, 270(2):711-718. doi:10.1007/s00405-012-2067-7, 10.1007/s00405-012-2067-7, 22692695.
17. Yang W, Song Y, Lu YL, Sun JZ, Wang HW. Increased expression of PD-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk HPV-related cervical intraepithelial neoplasia. Immunology 2013, 139(4):513-522. doi:10.1111/imm.12101, 10.1111/imm.12101, 23521696.
18. Clarke DT, Irving AT, Lambley EH, Payne E, McMillan NA. A novel method for screening viral interferon-resistance genes. J Interferon Cytokine Res 2004, 24(8):470-477. 10.1089/1079990041689610, 15320960.
19. Lee BN, Follen M, Shen DY, Malpica A, Adler-Storthz K, Shearer WT, Reuben JM. Depressed type 1 cytokine synthesis by superantigen-activated CD4+ T cells of women with human papillomavirus-related high-grade squamous intraepithelial lesions. Clin Diagn Lab Immunol 2004, 11(2):239-244. 371191, 15013969.
20. Alcocer-González JM, Berumen J, Taméz-Guerra R, Bermúdez-Morales V, Peralta-Zaragoza O, Hernández-Pando R, Moreno J, Gariglio P, Madrid-Marina V. Vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol 2006, 19(3):481-491. 10.1089/vim.2006.19.481, 16987066.
21. Deng W, Tsao SW, Kwok YK, Wong E, Huang XR, Liu S, Tsang CM, Ngan HY, Cheung AN, Lan HY, Guan XY, Cheung AL. Transforming growth factor beta1 promotes chromosomal instability in human papillomavirus 16 E6E7-infected cervical epithelial cells. Cancer Res 2008, 68(17):7200-7209. doi:10.1158/0008-5472.CAN-07-6569, 10.1158/0008-5472.CAN-07-6569, 18757436.
22. Gage JR, Sandhu AK, Nihira M, Bonecini-Almeida M, Da G, Cristoforoni P, Kishimoto T, Montz FJ, Martínez-Maza O. Effects of human papillomavirus-associated cells on human immunodeficiency vitrus gene expression. Obstet Gynecol 2000, 96(6):879-885. 10.1016/S0029-7844(00)01057-7, 11084171.
23. D'Anna R, Le Buanec H, Brizzini B, Burny A, Giannouli C, Zagury JF, Gallo RC, Zagury D, D'Alessio P. Human papillomavirus-16-E7 oncoprotein enhances the expression of adhesion molecules in cervical endothelial cells but not in human. J Hum Virol 2001, 4(2):85-95.
24. Woodworth CD, McMullin E, Iglesias M, Plowman GD. Interleukin 1 alpha and tumor necrosis factor alpha stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-imortalized and carcinoma-derivad cervical epithelial cells. Proc Natl Acad Sci U S A 1995, 92(7):2840-2844. 10.1073/pnas.92.7.2840, 42314, 7708734.
25. DiPaolo JA, Woodworth CD, Coutlée F, Zimonic DB, Bryant J, Kessous A. Relationship of stable integration of herpes simplex virus-2 Bg/II N subfragment Xho2 to malignant transformation of human papillomavirus-immortalized cervical keratinocytes. Int J Cancer 1998, 76(6):865-871. 10.1002/(SICI)1097-0215(19980610)76:6<865::AID-IJC16>3.0.CO;2-1, 9626354.
26. Pisani S, Fioriti D, Conte MP, Chiarini F, Seganti L, Degener AM. Involvement of herpes simplex type 2 in modulation of gene expression of human papillomavirus type 18. Int J Immunopathol Pharmacol 2002, 15(1):59-63.
27. Smith JS, Herrero R, Bosetti C, Munoz N, Bosch FX, Eluf-Neto J, Castellsague X, Meijer CJ, Van Den Brule AJ, Franceschi S, Ashley R. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002, 94(21):1604-1613. 10.1093/jnci/94.21.1604, 12419786.
28. Zhao Y, Cao X, Zheng Y, Tang J, Cai W, Wang H, Gao Y, Wang Y. Relationship between cervical disease and infection with human papillomavirus types 16 and 18, and herpes simplex virus 1 and 2. J Med Virol 2012, 84(12):1920-1927. 10.1002/jmv.23353, 23080497.
29. Zereu M, Zettler CG, Cambruzzi E, Zelmanowicz A. Herpes simplex virus type 2 and Chlamydia trachomatis in adenocarcinoma of the uterine cervix. Gynecol Oncol 2007, 105(1):172-175. 10.1016/j.ygyno.2006.11.006, 17188342.
30. Kwaśniewska A, Korobowicz E, Zdunek M, Skoczyński M, Kwaśniewski W, Daniłoś J, Goździcka-Józefiak A. Prevalence of Chlamydia trachomatis and herpes simplex virus 2 in cervical carcinoma associated with human papillomavirus detected in paraffin-sectioned samples. Eur J Gynaecol Oncol 2009, 30(1):65-70.
31. Nikitina OE, Lazarenko LM, Nikitin EV, Demchenko OM, Kovtonyuk GV, Ganova LO, Shevchuk V, Spivak MY. Infection of patients with cervical precancer by papillomaviruses and herpes simplex virus. Current Infection 2013, 3:43-47.
32. Reid A, Stanhope CR, Huschman BR. Colposcopia. Amer J Obstet Gynecol 1984, 149:815-823.
33. Meisels A, Fortin R. Condilomatosis lesions of cervix and vagina. Cytol Pat Acta Cytol 1986, 20:505-509.
34. Koss LG, Suhrland MJ. Atypical hyperplasia and other abnormalities of prostatic epithelium. Hum Pathol 1993, 24(8):817-818. 10.1016/0046-8177(93)90130-9, 8375852.
35. Bais AG, Beckmann I, Ewing PC, Eijkemans MJ, Meijer CJ, Snijders PJ, Helmerhorst TJ. Cytokine release in HR-HPV(+) women without and with cervical dysplasia (CIN II and III) or carcinoma, compared with HR-HPV(-) controls. Mediators Inflamm 2007, 2007:24147. doi:10.1155/2007/24147, 2220028, 18288269.
36. Bais AG, Beckmann I, Lindemans J, Ewing PC, Meijer CJ, Snijders PJ, Helmerhorst TJ. A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol 2005, 58(10):1096-1100. 10.1136/jcp.2004.025072, 1770745, 16189158.
37. Hara Y, Kimoto T, Okuno Y, Minekawa Y. Effect of herpes simplex virus on the DNA of human papillomavirus 18. J Med Virol 1997, 53(1):4-12. 10.1002/(SICI)1096-9071(199709)53:1<4::AID-JMV2>3.0.CO;2-4, 9298725.
38. Shi YJ, Yang J, Yang W. Mechanistic investigation of immunosuppression in patients with condyloma acuminate. Mol Med Rep 2013, 8(2):480-486.
39. Iancu IV, Botezatu A, Goia-Ruşanu CD, Stănescu A, Huică I, Nistor E, Anton G, Pleşa A. TGF-beta signalling pathway factors in HPV-induced cervical lesions. Roum Arch Microbiol Immunol 2010, 69(3):113-118.
40. Berezhnaya NM, Chekhun VF. Immunology of malignant growth 2005, Kyiv: Naukova Dumka.
41. Piestrzeniewicz-Ulanska D, Brys M, Semszuk A, Jakowicki JA, Krajewska WM. Exspression of TGF-beta type I and II reseptor in normal and cancerous human endothelium. Cancer Lett 2002, 186(2):213-239.
42. Baritaki S, Sifakis S, Huerta-Yepez S, Neonakis IK, Soufla G, Bonavida B, Spandidos DA. Overexpression of VEGF and TGF-beta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. Int J Oncol 2007, 31(1):69-79.
43. Feng Q, Wei H, Morihara J, Stern J, Yu M, Kiviat N, Hellstrom I, Hellstrom KE. Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. Gynecol Oncol 2012, 127(2):412-419. 10.1016/j.ygyno.2012.07.098, 3472044, 22828962.
44. Bubnov RV. Evidence-based pain management: is the concept of integrative medicine applicable?. EPMA J 2012, 3:13. 10.1186/1878-5085-3-13, 3533862, 23088743.
45. Hiraku Y, Tabata T, Ma N, Murata M, Ding X, Kawanishi S. Nitrative and oxidative DNA damage in cervical intraepithelial neoplasia associated with human papilloma virus infection. Cancer Sci 2007, 98(7):964-972. 10.1111/j.1349-7006.2007.00497.x, 17488337.
46. Shera KA, Shera CA, McDougall JK. Small tumor virus genomes are integrated near nuclear matrix attachment regions in transformed cells. J Virol 2001, 75:12339-12346. doi:10.1128/JVI.75.24.12339-12346.2001, 10.1128/JVI.75.24.12339-12346.2001, 116130, 11711624.
47. Wang T, Chang P, Wang L, Yao Q, Guo W, Chen J, Yan T, Cao C. The role of human papillomavirus infection in breast cancer. Med Oncol 2012, 29(1):48-55. 10.1007/s12032-010-9812-9, 21318737.
48. Popescu NC, Zimonjic DB. Chromosome-mediated alterations of the MYC gene in human cancer. J Cell Mol Med 2002, 6:151-159. doi:10.1111/j.1582-4934.2002.tb00183.x, 10.1111/j.1582-4934.2002.tb00183.x, 12169201.
49. Villiers EM, Sandstrom RE, Zur Hausen H. Presence of papillomavirus sequences in Lawson JS, Günzburg WH, Whitaker NJ. Viruses and human breast cancer. Future Microbiol 2006, 1:33-51. doi:10.2217/17460913.1.1.33, 10.2217/17460913.1.1.33, 17661684.
50. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007, 370(9590):890-907. 10.1016/S0140-6736(07)61416-0, 17826171.
51. Shapira N. Women's higher health risks in the obesogenic environment: a gender nutrition approach to metabolic dimorphism with predictive, preventive, and personalised medicine. EPMA J 2013, 4:1. 10.1186/1878-5085-4-1, 3560240, 23311512.
52. Cebioglu M, Schild HH, Golubnitschaja O. Cancer predisposition in diabetics: risk factors considered for predictive diagnostics and targeted preventive measures. EPMA J 2010, 1(1):130-137. 10.1007/s13167-010-0015-4, 3405313, 23199047.
53. Spivak MY, Bubnov RV, Yemets IM, Lazarenko LM, Timoshok NO, Ulberg ZR. Gold nanoparticles - the theranostic challenge for PPPM: nanocardiology application. EPMA J 2013, 4:18. 10.1186/1878-5085-4-18, 3702527, 23800174.
54. Spivak MY, Bubnov RV, Yemets IM, Lazarenko LM, Tymoshok NO, Ulberg ZR. Development and testing of gold nanoparticles for drug delivery and treatment of heart failure: a theranostic potential for PPP cardiology. EPMA J 2013, 4:20. 10.1186/1878-5085-4-20, 3751918, 23889805.
55. Ivanov VK, Shcherbakov AB, Baranchikov EB, Kozyk VV. Nanocrystaline ceria properties, synthesis, applications. In Edited by Spivak MY, Tretyakov YD 2013, Tomsk: Publishing house of University of Tomsk, 978-5-7511-2182-2.
56. Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, Edmunds WJ, Claeys P, Goldenthal KL, Harper DM, Markowitz L. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ 2007, 85:719-726. 10.2471/BLT.06.038414, 2636411, 18026629.
57. Ault KA, Future II, . Study Group, authors Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet 2007, 369:1861-1868. 10.1016/S0140-6736(07)60852-6, 17544766, Study Group, authors.
58. Melnik IM. Genetic algorithm for solving the problem of an optimum regression model construction as a discrete optimization problem. J Autom Inf Sci 2008, 40(6):60-71.
59. Melnyk IM, Bubnov RV. Choice of diagnostic decision making in medicine and intervention mistake prediction using mathematical models. Int J Inf Models Anal 2012, 1(1):78-83.
60. McCluggage WG. Recent advances in immunohistochemistry in gynecological pathology. Histopathology 2002, 40(4):309-326. 10.1046/j.1365-2559.2002.01384.x, 11943015.
61. Kelloff GJ, Sigman CC, Johnson KM, Boone CW, Greenwald P, Crowell JA, Hawk ET, Doody LA. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev 2000, 9(2):127-137.
62. Murphy N, Ring M, Heffron CC, King B, Killalea AG, Hughes C, Martin CM, McGuinness E, Sheils O, O'Leary JJ. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol 2005, 58:525-534. doi:10.1136/jcp.2004.018895, 10.1136/jcp.2004.018895, 1770660, 15858126.
63. Lacey JV, Brinton LA, Abbas FM, Barnes WA, Gravitt PE, Greenberg MD, Greene SM, Hadjimichael OC, McGowan L, Mortel R, Schwartz PE, Silverberg SG, Hildesheim A. Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 1999, 8(12):1079-1085.
64. Serrano ML, Umaña-Pérez A, Garay-Baquero DJ, Sánchez-Gómez M. New biomarkers for cervical cancer - perspectives from the IGF system. Topics on Cervical Cancer With an Advocacy for Prevention 2012, 284. Europe: InTech, Rajamanickam R, ISBN 978-953-51-0183-3.
65. Gadducci A, Tana R, Cosio S, Genazzani AR. The serum assay of tumor markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol 2008, 66(1):10-20. 10.1016/j.critrevonc.2007.09.002, 17964182.
66. Vieira SC, Seferino LC, Da Silva BB, Aparecida Pinto G, Vasallo J, Carvasan GA, De Moraes NG. Quantification of angiogenesis in cervical cancer: a comparison among three endothelial cell markers. Gynecol Oncol 2004, 93(1):121-124. 10.1016/j.ygyno.2004.01.033, 15047224.
67. Traweek ST, Kandalaft PL, Mehta P, Battifora H. The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. Am J Clin Pathol 1991, 96(1):25-31.
68. Yim EK, Park JS. Role of proteomics in translational research in cervical cancer. Expert Rev Proteomics 2006, 3(1):21-36. 10.1586/14789450.3.1.21, 16445348.
69. Di Domenico F, De Marco F, Perluigi M. Proteomics strategies to analyze HPV-transformed cells: relevance to cervical cancer. Expert Rev Proteomics 2013, 10(5):461-472. doi:10.1586/14789450.2013.842469, 10.1586/14789450.2013.842469, 24117203.
70. Cole LA. Immunoassay of human chorionic gonadotropin, its free subunits, and metabolites. Clin Chem 1997, 43:2233-2243.
71. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998, 396:84-88. 10.1038/23962, 9817205.
72. Choi YP, Kang S, Hong S, Xie X, Cho NH. Proteomic analysis of progressive factors in uterine cervical cancer. Proteomics 2005, 5(6):1481-1493. 10.1002/pmic.200401021, 15838902.
73. Marco FD. Oxidative stress and HPV carcinogenesis. Viruses 2013, 5:708-731. doi:10.3390/v5020708., 10.3390/v5020708, 3640522, 23403708.
74. Zegels G, Van Raemdonk GA, Coen EP, Tjalma WA, Van Ostade XW. Comprehensive proteomic analysis of human cervical-vaginal fluid using colposcopy samples. Proc Natl Acad Sci U S A 2009, 17(7):17.
75. Payne GS, Schmidt M, Morgan VA, Giles S, Bridges J, Ind T, DeSouza NM. Evaluation of magnetic resonance diffusion and spectroscopy measurements as predictive biomarkers in stage 1 cervical cancer. Gynecol Oncol 2010, 116(2):246-252. 10.1016/j.ygyno.2009.09.044, 19875159.
76. Chopra S, Verma A, Kundu S, Engineer R, Medhi S, Mahantshetty U, Gupta S, Shrivastava SK. Evaluation of diffusion-weighted imaging as a predictive marker for tumor response in patients undergoing chemoradiation for postoperative recurrences of cervical cancer. J Cancer Res Ther 2012, 8(1):68-73. doi:10.4103/0973-1482.95177, 10.4103/0973-1482.95177, 22531517.
77. Son H, Kositwattanarerk A, Hayes MP, Chuang L, Rahaman J, Heiba S, Machac J, Zakashansky K, Kostakoglu L. PET/CT evaluation of cervical cancer: spectrum of disease. Radiographics 2010, 30(5):1251-1268. doi:10.1148/rg.305105703, 10.1148/rg.305105703, 20833849.
78. Herrera FG, Prior JO. The role of PET/CT in cervical cancer. Front Oncol 2013, 3:34. doi:10.3389/fonc.2013.00034, 3581867, 23549376.
79. Schöder H, Gönen M. Screening for cancer with PET and PET/CT: potential and limitations. J Nucl Med 2007, 48(Suppl 1):4S-18S.
80. Thomas A, Kümmel S, Fischer T, Gemeinhardt O. Real-time sonoelastography of the cervix: tissue elasticity of the normal and abnormal cervix. Acad Radiol 2007, 14:193-200. 10.1016/j.acra.2006.11.010, 17236992.
81. Myers KM, Socrate S, Paskaleva A, House M. A study of the anisotropy and tension/compression behavior of human cervical tissue. J Biomech Eng 2010, 132:021003. 10.1115/1.3197847, 20370240.
82. Belitsos P, Papoutsis D, Rodolakis A, Mesogitis S, Antsaklis A. Three-dimensional power Doppler ultrasound for the study of cervical cancer and precancerous lesions. Ultrasound Obstet Gynecol 2012, 40(5):576-581. doi:10.1002/uog.11134, 10.1002/uog.11134, 22323111.
83. Xiuhua Y, Hong S, Li L, Aifen X, Hong Z. The diagnostic value of transvaginal color doppler sonography in cervical lesions. Chin J Med Imaging 2006, 1:001.
84. Tjalma W, Sonnemans H, Weyler J, Van Marck E, Van Daele A, van Dam P. Angiogenesis in cervical epithelial neoplasia and the risk of recurrence. American Am J Obstet Gynecol 1999, 181(3):554-559.
85. Lushchyk UB, Novytskyy VV, Babii IP, Lushchyk NG, Riabets LS. Predictive and preventive strategies to advance the treatments of cardiovascular and cerebrovascular diseases: the Ukrainian context. EPMA J 2012, 3:12. 10.1186/1878-5085-3-12, 3565889, 23083430.
86. Nida DL, Rahman MS, Carlson KD, Richards-Kortum R, Follen M. Fluorescent nanocrystals for use in early cervical cancer detection. Gynecol Oncol 2005, 99(3):S89-S94. 10.1016/j.ygyno.2005.07.050, 16139342.
87. Kuramitsu Y, Nakamura K. Proteomic analysis of cancer tissues: shedding light on carcinogenesis and possible biomarkers. Proteomics 2006, 6:5650-5661. 10.1002/pmic.200600218, 16972299.
88. Hwang ES, Kim GH. Biomarkers for oxidative stress status of DNA, lipids, and proteins in vitro and in vivo cancer research. Toxicology 2007, 5(1-2):1-10.
89. Dalle-Donne I, Scaloni A, Giustarini D, Cavarra E, Tell G, Lungarella G, Colombo R, Rossi R, Milzani A. Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics. Mass Spectrom Rev 2005, 24(1):55-99. 10.1002/mas.20006, 15389864.
90. Ogino K, Wang DH. Biomarkers of oxidative/nitrosative stress: an approach to disease prevention. Acta Med Okayama 2007, 61(4):181-9.
91. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003, 3(2):110-6. 10.1038/nrc990, 12563310.
92. Yeghiazaryan K, Flammer J, Golubnitschaja O. Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costs. EPMA J 2010, 1(2):263-72. 10.1007/s13167-010-0032-3, 3405317, 23199064.
93. Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, Lieber A, Kiviat N. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev 2006, 15(1):114-23. 10.1158/1055-9965.EPI-05-0323, 16434596.
94. Said N, Theodorescu D. Secreted protein acidic and rich in cysteine (SPARC) in Cancer. J Carcinogene Mutagene 2013, 4:151. doi:10.4172/2157-2518.1000151.
95. McIntyre-Seltman K, Lesnock JL. Cervical cancer screening in pregnancy. Obstet Gynecol Clin North Am 2008, 35(4):645-58. 10.1016/j.ogc.2008.10.003, 19061823.
96. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
97. Bloom DE, Cafiero ET, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S, Feigl AB, Gaziano T, Mowafi M, Pandya A, Prettner K, Rosenberg L, Seligman B, Stein AZ, Weinstein C. The Global Economic Burden of Noncommunicable Diseases 2011, Geneva: World Economic Forum.
98. Myers ER. The economic impact of HPV vaccines: not just cervical cancer. Am J Obstet Gynecol 2008, 198(5):487-488. doi:10.1016/j.ajog.2008.03.056, 10.1016/j.ajog.2008.03.056, 18455522.
99. Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008, 198(5):e1-e7. 10.1016/j.ajog.2008.03.064.
100. Boulet GA, Horvath CA, Berghmans S, Bogers J. Human papillomavirus in cervical cancer screening: important role as biomarker. Cancer Epidemiol Biomarkers Prev 2008, 17(4):810-817. doi:10.1158/1055-9965.EPI-07-2865, 10.1158/1055-9965.EPI-07-2865, 18398022.